human immunodefici viru hiv retroviru caus acquir immun defici syndrom ( aid ) , condit immun system begin fail , lead life-threaten opportunist infect . previou name viru includ human t-lymphotrop virus-iii ( htlv-iii ) lymphadenopathy-associ viru ( lav ) . infect hiv occur transfer blood , semen , vagin fluid , cowper 's fluid breast milk . within bodi fluid hiv present free viru particl viru within infect immun cell . three major rout transmiss unprotect sexual intercours , contamin needl transmiss infect mother babi birth breast milk . screen blood product hiv develop world larg elimin transmiss blood transfus infect blood product countri . hiv infect human pandem . januari 2006 , joint unit nation programm hiv/aid ( unaid ) world health organ ( ) estim aid kill 25 million peopl sinc first recogn decemb 1 , 1981 , make one destruct pandem record histori . 2005 alon , aid claim estim 2.4-3.3 million life , 570,000 child . third death occur sub-saharan africa , retard econom growth increas poverti . accord current estim , hiv set infect 90 million peopl africa , result minimum estim 18 million orphan . antiretrovir treatment reduc mortal morbid hiv infect , routin access antiretrovir medic avail countri . hiv primarili infect vital cell human immun system helper cell ( specif cd4 + cell ) , macrophag dendrit cell . hiv infect lead low level cd4 + cell three main mechan : firstli , direct viral kill infect cell ; secondli , increas rate apoptosi infect cell ; thirdli , kill infect cd4 + cell cd8 cytotox lymphocyt recogn infect cell . cd4 + cell number declin critic level , cell-medi immun lost , bodi becom progress suscept opportunist infect . untreat , eventu hiv-infect individu develop aid die ; howev one ten remain healthi mani year , notic symptom . treatment anti-retrovir , avail , increas life expect peopl infect hiv . hope current futur treatment may allow hiv-infect individu achiev life expect approach gener public ( see treatment ) . # # origin discoveri aid epidem discov june 5 , 1981 , u.s. center diseas control prevent report cluster pneumocysti carinii pneumonia ( classifi pneumocysti jiroveci pneumonia ) five homosexu men lo angel . diseas origin dub grid , gay-rel immun defici , health author soon realiz nearli half peopl identifi syndrom homosexu men . 1982 , cdc introduc term aid describ newli recogn syndrom , though still casual refer grid . 1983 , scientist led luc montagni pasteur institut franc first discov viru caus aid . call lymphadenopathy-associ viru ( lav ) . year later team led robert gallo unit state confirm discoveri viru , renam human lymphotrop viru type iii ( htlv-iii ) . dual discoveri led consider scientif disagr , presid mitterrand franc presid reagan usa met major issu resolv . 1986 , french us name viru drop favour new term , human immunodefici viru ( hiv ) . hiv classifi member genu lentiviru , part famili retrovirida . lentivirus mani common morpholog biolog properti . mani speci infect lentivirus , characterist respons long-dur ill long incub period . lentivirus transmit single-strand , positive-sens , envelop rna viru . upon entri target cell , viral rna genom convert double-strand dna viral encod revers transcriptas present viru particl . viral dna integr cellular dna viral encod integras genom transcrib . viru infect cell , two pathway possibl : either viru becom latent infect cell continu function , viru becom activ replic , larg number viru particl liber infect cell . two speci hiv infect human : hiv-1 hiv-2 . hiv-1 thought origin southern cameroon jump wild chimpanze ( pan troglodyt troglodyt ) human twentieth centuri . hiv-2 may origin sooti mangabey ( cercocebu ati ) , old world monkey guinea-bissau , gabon , cameroon . hiv-1 virul . easili transmit caus major hiv infect global . hiv-2 less transmitt larg confin west africa . hiv-1 viru initi discov term lav . three earliest known instanc hiv-1 infect follow : plasma sampl taken 1959 adult male live democrat republ congo . hiv found tissu sampl 15 year old african-american teenag die st. loui 1969 . hiv found tissu sampl norwegian sailor die around 1976 . although varieti theori exist explain transfer hiv human , singl hypothesi wide accept , topic remain controversi . freelanc journalist tom curti discuss one controversi possibl origin hiv/aid 1992 roll stone magazin articl . put forward known opv aid hypothesi , suggest aid inadvert caus late 1950 belgian congo hilari koprowski 's research polio vaccin . although subsequ retract due libel issu surround claim , roll stone articl motiv anoth freelanc journalist , edward hooper , probe deepli subject . hooper 's research result publish 1999 book , river , alleg experiment oral polio vaccin prepar use chimpanze kidney tissu rout simian immunodefici viru ( siv ) cross human becom hiv , thu start human aid pandem . theori contradict analysi genet mutat primat lentiviru strain indic 95 % certainti origin hiv-1 strain date 1930 . # # transmiss sinc begin pandem , three main transmiss rout hiv identifi : sexual rout . major hiv infect acquir unprotect sexual relat . sexual transmiss occur infect sexual secret one partner come contact rectal , genit oral mucou membran anoth . blood blood product rout . transmiss rout account infect intraven drug user , hemophiliac recipi blood transfus ( though transfus check hiv develop world ) blood product . also concern person receiv medic care region preval substandard hygien use inject equip , reus needl third world countri . health care worker nurs , laboratori worker , doctor , also infect , although occur rare . peopl give receiv tattoo , pierc scarif procedur also risk infect . mother-to-child transmiss ( mtct ) . transmiss viru mother child occur utero last week pregnanc childbirth . absenc treatment , transmiss rate mother child 25 % . howev , drug treatment cesarian section avail , reduc 1 % . breast feed also present risk infect babi . hiv-2 transmit much less frequent mtct sexual rout hiv-1 . hiv found low concentr saliva , tear urin infect individu , risk transmiss secret neglig . use physic barrier latex condom wide advoc reduc sexual transmiss hiv . spermicid use alon vagin contracept like diaphragm actual increas male femal transmiss rate due inflamm vagina , consid barrier infect . current research clarifi relationship male circumcis hiv differ social cultur context . even though male circumcis may lead reduct infect risk heterosexu men 60 % , unaid belief prematur recommend male circumcis part hiv prevent program . south african medic expert concern repeat use unsteril blade ritual circumcis adolesc boy may spread hiv . # # structur genom hiv differ structur retroviru . 120 nm diamet ( 120 billionth meter ; around 60 time smaller red blood cell ) roughli spheric . compos two copi posit single-strand rna code viru 's nine gene enclos conic capsid compos 2,000 copi viral protein , p24 . single-strand rna tightli bound nucleocapsid protein , p7 enzym need develop virion revers transcriptas , proteas integras . matrix compos viral protein p17 surround capsid ensur integr virion particl . , turn , surround viral envelop compos two layer fatti molecul call phospholipid taken membran human cell newli form viru particl bud cell . embed viral envelop protein host cell 70 copi complex hiv protein protrud surfac viru particl . protein , known env , consist cap made three molecul call glycoprotein ( gp ) 120 , stem consist three gp41 molecul anchor structur viral envelop . glycoprotein complex enabl viru attach fuse target cell initi infecti cycl . surfac protein , especi gp120 , consid target futur treatment vaccin hiv . nine gene encod within rna genom , three gene , gag , pol , env , contain inform need make structur protein new viru particl . env , exampl , code protein call gp160 broken viral enzym form gp120 gp41 . six remain gene , tat , rev , nef , vif , vpr , vpu ( vpx case hiv-2 ) , regulatori gene protein control abil hiv infect cell , produc new copi viru ( replic ) , caus diseas . protein encod nef , instanc , appear necessari viru replic effici , vpu -encod protein influenc releas new viru particl infect cell . end strand hiv rna contain rna sequenc call long termin repeat ( ltr ) . region ltr act switch control product new viru trigger protein either hiv host cell . # # tropism term viral tropism refer cell type hiv infect . hiv infect varieti immun cell cd4 + cell , macrophag , microgli cell . hiv-1 entri macrophag cd4 + cell mediat interact virion envelop glycoprotein ( gp120 ) cd4 molecul target cell also chemokin coreceptor . macrophag ( m-tropic ) strain hiv-1 , non- syncitia-induc strain ( nsi ) use β -chemokin receptor ccr5 entri thu abl replic macrophag cd4 + cell . ccr5 coreceptor use almost primari hiv-1 isol regardless viral genet subtyp . inde , macrophag play key role sever critic aspect hiv infect . appear first cell infect hiv perhap sourc hiv product cd4 + cell becom deplet patient . macrophag microgli cell cell infect hiv central nervou system . tonsil adenoid hiv-infect patient , macrophag fuse multinucl giant cell produc huge amount viru . t-tropic isol , syncitia-induc ( si ) strain replic primari cd4 + cell well macrophag use α -chemokin receptor , cxcr4 , entri . α -chemokin , sdf-1 , ligand cxcr4 , suppress replic t-tropic hiv-1 isol . down-regul express cxcr4 surfac cell . hiv use ccr5 receptor term r5 , use cxcr4 term x4 , use , x4r5 . howev , use coreceptor alon explain viral tropism , r5 viru abl use ccr5 macrophag product infect hiv also infect subtyp myeloid dendrit cell , probabl constitut reservoir maintain infect cd4 + cell number declin extrem low level . peopl resist certain strain hiv . one exampl occur peopl ccr5-δ32 mutat ; peopl resist infect r5 viru mutat stop hiv bind coreceptor , reduc abil infect target cell . heterosexu intercours major mode hiv transmiss . x4 r5 hiv present semin fluid pass partner partner . virion infect numer cellular target dissemin whole organ . howev , select process lead predomin transmiss r5 viru pathway . select process work still investig , one model spermatozoon may select carri r5 hiv possess ccr3 ccr5 cxcr4 surfac genit epitheli cell preferenti sequest x4 viru . patient infect subtyp b hiv-1 , often co-receptor switch late-stag diseas t-tropic variant appear infect varieti cell cxcr4 . variant replic aggress heighten virul caus rapid cell deplet , immun system collaps , opportunist infect mark advent aid . thu , cours infect , viral adapt use cxcr4 instead ccr5 may key step progress aid . number studi subtyp b-infect individu determin 40 50 % aid patient harbour viru si , presum x4 , phenotyp . # # replic cycl # # # entri cell hiv enter macrophag cd4 + cell adsorpt glycoprotein surfac receptor target cell follow fusion viral envelop cell membran releas hiv capsid cell . interact trimer envelop complex ( gp160 spike , discuss ) cd4 chemokin receptor ( gener either ccr5 cxcr4 other known interact ) cell surfac . gp160 spike contain bind domain cd4 chemokin receptor . first step fusion involv high-affin attach cd4 bind domain gp120 cd4 . gp120 bound cd4 protein , envelop complex undergo structur chang , expos chemokin bind domain gp120 allow interact target chemokin receptor . allow stabl two-prong attach , allow n-termin fusion peptid gp41 penetr cell membran . repeat sequenc gp41 , hr1 hr2 interact , caus collaps extracellular portion gp41 hairpin . loop structur bring viru cell membran close togeth , allow fusion membran subsequ entri viral capsid . hiv bound target cell , hiv rna variou enzym , includ revers transcriptas , integras proteas , inject cell . hiv infect dendrit cell ( dc ) cd4-ccr5 rout , anoth rout use mannose-specif c-type lectin receptor dc-sign also use . dc one first cell encount viru sexual transmiss . current thought play import role transmit hiv cell viru captur mucosa dc . # # # replic transcript viral capsid enter cell , enzym call revers transcriptas liber single-strand ( + ) rna attach viral protein copi complementari dna 9 kb size . process revers transcript extrem error-pron step mutat may occur . mutat may caus drug resist . revers transcriptas make complementari dna strand form double-strand viral dna intermedi ( vdna ) . vdna transport cell nucleu . integr viral dna host cell 's genom carri anoth viral enzym call integras . integr viral dna may lie dormant , latent stage hiv infect . activ produc viru , certain cellular transcript factor need present , import nf- κ b ( nf kappa b ) , upregul cell becom activ . mean cell like kill hiv fact current fight infect . replic process , integr proviru copi mrna splice smaller piec . small piec produc regulatori protein tat ( encourag new viru product ) rev . rev accumul gradual start inhibit mrna splice . stage , structur protein gag env produc full-length mrna . full-length rna actual viru genom ; bind gag protein packag new viru particl . hiv-1 hiv-2 appear packag rna differ ; hiv-1 bind appropri rna wherea hiv-2 preferenti bind mrna use creat gag protein . may mean hiv-1 better abl mutat ( hiv-1 infect progress aid faster hiv-2 infect respons major global infect ) . # # # assembl releas final step viral cycl , assembl new hiv-1 viron , begin plasma membran host cell . env polyprotein ( gp160 ) go endoplasm reticulum transport golgi complex cleav proteas process two hiv envelop glycoprotein gp41 gp120 . transport plasma membran host cell gp41 anchor gp120 membran infect cell . gag ( p55 ) gag-pol ( p160 ) polyprotein also associ inner surfac plasma membran along hiv genom rna form virion begin bud host cell . matur either occur form bud immatur virion bud host cell . matur , hiv proteas cleav polyprotein individu function hiv protein enzym . variou structur compon assembl produc matur hiv virion . cleavag step inhibit proteas inhibitor . matur viru abl infect anoth cell . # # genet variabl hiv differ mani viru high genet variabl . divers result fast replic cycl , gener 10 9 10 10 virion everi day , coupl high mutat rate approxim 3 x 10 -5 per nucleotid base per cycl replic recombinogen properti revers transcriptas . complex scenario lead gener mani variant hiv singl infect patient cours one day . variabl compound singl cell simultan infect two differ strain hiv . simultan infect occur , genom progeni virion may compos rna strand two differ strain . hybrid virion infect new cell undergo replic . happen , revers transcriptas , jump back forth two differ rna templat , gener newli synthes retrovir dna sequenc recombin two parent genom . recombin obviou occur subtyp .. close relat simian immunodefici viru ( siv ) exhibit somewhat differ behaviour : natur host , african green monkey sooti mangabey , retroviru present high level blood , evok mild immun respons , caus develop simian aid , undergo extens mutat recombin typic hiv . contrast , infect heterolog host ( rhesu cynomologu macaqu ) siv result gener genet divers order hiv infect human ; heterolog host also develop simian aid . relationship , , genet diversif , immun respons , diseas progress unknown . three group hiv-1 identifi basi differ env : , n , . group preval subdivid eight subtyp ( clade ) , base whole genom , geograph distinct . preval subtyp b ( found mainli north america europ ) , ( found mainli africa ) , c ( found mainli africa asia ) ; subtyp form branch phylogenet tree repres lineag group hiv-1 . coinfect distinct subtyp give rise circul recombin form ( crf ) . 2000 , last year analysi global subtyp preval made , 47.2 % infect worldwid subtyp c , 26.7 % subtyp a/crf02_ag , 12.3 % subtyp b , 5.3 % subtyp , 3.2 % crf_ae , remain 5.3 % compos subtyp crf . hiv-1 research focus subtyp b ; laboratori focu subtyp . genet sequenc hiv-2 partial homolog hiv-1 close resembl siv hiv-1 . # # clinic cours infect infect hiv-1 associ progress decreas cd4 + cell count increas viral load . stage infect determin measur patient 's cd4 + cell count , level hiv blood . initi infect hiv gener occur transfer bodi fluid infect person uninfect one . first stage infect , primari , acut infect , period rapid viral replic immedi follow individu 's exposur hiv lead abund viru peripher blood level hiv commonli approach sever million viru per ml . respons accompani mark drop number circul cd4 + cell . acut viremia associ virtual patient activ cd8 + cell , kill hiv-infect cell , subsequ antibodi product , seroconvers . cd8 + cell respons thought import control viru level , peak declin , cd4 + cell count rebound around 800 cell per ml ( normal valu 1200 cell per ml ) . good cd8 + cell respons link slower diseas progress better prognosi , though elimin viru . period individu ( 80 90 % ) develop influenza-lik ill symptom fever , malais , lymphadenopathi , pharyng , headach , myalgia , sometim rash . nonspecif natur ill , often recogn sign hiv infect . even patient go doctor hospit , often misdiagnos one common infecti diseas symptom . consequ , primari symptom use diagnos hiv infect develop case mani caus common diseas . howev , recogn syndrom import patient much infecti period . strong immun defens reduc number viral particl blood stream , mark start infect 's clinic latenc stage . clinic latenc vari two week 20 year . earli phase infect , hiv activ within lymphoid organ , larg amount viru becom trap follicular dendrit cell ( fdc ) network . surround tissu rich cd4 + cell may also becom infect , viral particl accumul infect cell free viru . individu phase still infecti . time , cd4 + cd45ro + cell carri provir load . cd4 + cell number declin critic level , cell-medi immun lost , infect varieti opportunist microb appear . first symptom often includ moder unexplain weight loss , recur respiratori tract infect ( sinus , bronchiti , otiti medium , pharyng ) , oral ulcer . common opportunist infect tumor , normal control robust cd4 + cell-medi immun start affect patient . typic , resist lost earli oral candida speci mycobacterium tuberculosi , lead increas susceptibilti oral candidiasi ( thrush ) tuberculosi . later , reactiv latent herp viru caus patient suffer shingl epstein-barr virus-induc b-cell lymphoma , kaposi 's sarcoma , tumor endotheli cell occur hiv protein tat interact human herpesvirus-8 . pneumonia caus fungu pneumocysti jiroveci common often fatal . final stage aid , infect cytomegaloviru ( anoth herp viru ) mycobacterium avium complex promin . patient aid get infect tumor , tumor infect less promin still signific . # # hiv test mani peopl unawar infect hiv . exampl , less 1 % sexual activ urban popul africa test proport even lower rural popul . furthermor , 0.5 % pregnant woman attend urban health facil counsel , test receiv test result . , proport even lower rural health facil . sinc donor may therefor unawar infect , donor blood blood product use medicin medic research routin screen hiv . hiv-1 test consist initi screen enzyme-link immunosorb assay ( elisa ) detect antibodi hiv-1 . specimen nonreact result initi elisa consid hiv-neg unless new exposur infect partner partner unknown hiv statu occur . specimen reactiv elisa result retest duplic . result either duplic test reactiv , specimen report repeatedli reactiv undergo confirmatori test specif supplement test ( e.g. , western blot , less commonli , immunofluoresc assay ( ifa ) ) . specimen repeatedli reactiv elisa posit ifa reactiv western blot consid hiv-posit indic hiv infect . specimen repeatedli elisa-react occasion provid indetermin western blot result , may either incomplet antibodi respons hiv infect person , nonspecif reaction uninfect person . although ifa use confirm infect ambigu case , assay wide use . gener , second specimen collect > 1 month later retest person indetermin western blot result . although much less commonli avail , nucleic acid test ( e.g. , viral rna provir dna amplif method ) also help diagnosi certain situat . addit , test specimen might provid inconclus result low quantiti specimen . situat , second specimen collect test hiv infect . # # treatment current vaccin cure hiv aid . known method prevent avoid exposur viru . howev , antiretrovir treatment , known post-exposur prophylaxi believ reduc risk infect begun directli exposur . current treatment hiv infect consist highli activ antiretrovir therapi , haart . highli benefici mani hiv-infect individu sinc introduct 1996 , proteas inhibitor-bas haart initi becam avail . current haart option combin ( `` cocktail '' ) consist least three drug belong least two type , `` class , '' anti-retrovir agent . typic , class two nucleosid analogu revers transcriptas inhibitor ( narti nrti ) plu either proteas inhibitor non-nucleosid revers transcriptas inhibitor ( nnrti ) . aid progress child rapid less predict adult , particularli young infant , aggress treatment recommend child adult . develop countri haart avail , doctor assess patient thoroughli : measur viral load , fast cd4 declin , patient readi . decid recommend start treatment . haart allow stabilis patient ’ symptom viremia , neither cure patient , allevi symptom , high level hiv-1 , often haart resist , return treatment stop . moreov , would take lifetim hiv infect clear use haart . despit , mani hiv-infect individu experienc remark improv gener health qualiti life , led larg reduct hiv-associ morbid mortal develop world . comput base studi 2006 project follow 2004 unit state treatment guidelin gave averag life expect hiv infect individu 32.1 year time infect treatment start cd4 count 350/µl . studi limit take account possibl futur treatment project confirm within clinic cohort set . absenc haart , progress hiv infect aid observ occur median nine ten year median surviv time develop aid 9.2 month . howev , haart sometim achiev far less optim result , circumst effect less fifti percent patient . due varieti reason medic intolerance/sid effect , prior ineffect antiretrovir therapi infect drug-resist strain hiv . howev , non-adher non-persist antiretrovir therapi major reason individu fail benefit haart . reason non-adher non-persist haart vari overlap . major psychosoci issu , poor access medic care , inadequ social support , psychiatr diseas drug abus contribut non-adher . complex haart regimen , whether due pill number , dose frequenc , meal restrict issu along side effect creat intent non-adher also contribut problem . side effect includ lipodystrophi , dyslipidaemia , insulin resist , increas cardiovascular risk birth defect . anti-retrovir drug expens , major world 's infect individu access medic treatment hiv aid . research improv current treatment includ decreas side effect current drug , simplifi drug regimen improv adher , determin best sequenc regimen manag drug resist . unfortun , vaccin thought abl halt pandem . vaccin would cost less , thu afford develop countri , would requir daili treatment . howev , 20 year research , hiv-1 remain difficult target vaccin . # # epidemiolog unaid estim aid kill 25 million peopl sinc first recogn 1981 , make one destruct pandem record histori . despit recent , improv access antiretrovir treatment care mani region world , aid pandem claim estim 2.8 million ( 2.4 3.3 million ) life 2005 half million ( 570,000 ) child . global , 33.4 46 million peopl current live hiv . 2005 , 3.4 6.2 million peopl newli infect 2.4 3.3 million peopl aid die , increas 2004 highest number sinc 1981 . sub-saharan africa remain far worst-affect region , estim 21.6 27.4 million peopl current live hiv . two million [ 1.5–3.0 million ] child younger 15 year age . 64 % peopl live hiv sub-saharan africa , three quarter woman live hiv . 2005 , 12.0 million [ 10.6–13.6 million ] aid orphan live sub-saharan africa 2005 . south & south east asia second-worst affect 15 % total . aid account death 500,000 child region . two-third hiv/aid infect asia occur india , estim 5.7 million infect ( estim 3.4–9.4 million ) ( 0.9 % popul ) , surpass south africa 's estim 5.5 million ( 4.9–6.1 million ) ( 11.9 % popul ) infect , make india countri highest number hiv infect world . 35 african nation highest preval , averag life expect 48.3 years—6.5 year less would without diseas . latest evalu report world bank 's oper evalu depart assess develop effect world bank 's country-level hiv/aid assist defin polici dialogu , analyt work , lend explicit object reduc scope impact aid epidem . first comprehens evalu world bank 's hiv/aid support countri , begin epidem mid-2004 . bank aim assist implement nation govern programm , experi provid import insight nation aid programm made effect . develop haart effect therapi hiv infect aid substanti reduc death rate diseas area drug wide avail . creat mispercept diseas gone away . fact , life expect person aid increas countri haart wide use , number person live aid increas substanti . unit state , number person aid increas 35,000 1988 220,000 1996 . africa , number mtct preval aid begin revers decad steadi progress child surviv . countri uganda attempt curb mtct epidem offer vct ( voluntari counsel test ) , pmtct ( prevent mother-to-child transmiss ) anc ( ante-nat care ) servic , includ distribut antiretrovir therapi . # # altern hypothesi small minor scientist activist question connect hiv aid , exist hiv , valid current test method . claim consid unsupport scientif commun , accus dissent select ignor evid favour hiv 's role aid irrespons pose threat public health discourag hiv test proven treatment . aid dissid assert current mainstream approach aid , base hiv causat , result inaccur diagnosi , psycholog terror , toxic treatment , squander public fund . dissid view wide reject , consid pseudosci mainstream scientif commun . # # protein involv treatment apobec3g